Is BLDE Stock a Buy as Blade Air Mobility Rebrands?

Blade Air Mobility (BLDE), the technology-driven air mobility platform, is set to enter a new chapter as its long-planned legal name change to Strata Critical Medical, takes effect this week. Effective yesterday, Aug. 28, the company will now operate under the new name, signaling a strategic shift toward medical and logistics services.

And starting today, Aug. 29, its shares will trade on Nasdaq under the ticker SRTA, with warrants listed as SRTAW. The development follows the completion of the previously announced sale of Blade’s Passenger business to Joby Aviation (JOBY), a transaction valued at up to $125 million and announced on Aug. 4.

The news sparked immediate investor enthusiasm, driving the stock up 17.2% on the day of the announcement. With the Passenger segment now divested, Blade Air is positioned to concentrate fully on its healthcare logistics operations, and market watchers are closely monitoring whether the strategic refocus will translate into renewed momentum for the stock.

The New York-based Blade Air Mobility (Strata Critical Medical) offers air transportation and logistics services tailored to hospitals and healthcare providers. With a market cap of roughly $386.4 million, its operations include helicopter and amphibious seaplane flights, nonmedical jet charters, and the transportation of human organs and medical personnel, as well as donor logistics coordination and support services.

The stock has performed strongly over the past year, gaining 52% in the last 52 weeks. Momentum remains robust, with a 37.6% increase over six months and a striking 9.7% rise in the past five trading days, underscoring momentum in the wake of strategic developments.

From a valuation standpoint, BLDE trades at 1.42 times sales, sitting well below the industry average. This highlights relative attractiveness for potential investors.

Blade Air reported its fiscal second-quarter 2025 results on Aug. 5, which topped Street’s expectations. Total revenue reached $70.8 million, up 4.2% year-over-year (YoY), surpassing analyst estimates of $64.08 million.

Growth was led by the Medical segment, which continues to gain traction as hospitals increasingly rely on timely organ transportation and donor coordination. Flight Profit increased 8.5% to $17.7 million, while Medical revenue surged 17.6% to $45.1 million, demonstrating the financial impact of the company’s strategic pivot.